KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.32
+1.89%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 15.0M | 244.1M | 3.5M | 151.0K | — |
| Cost of Revenue | 798.0K | 1.5M | — | — | — |
| Gross Profit | 14.2M | 242.6M | 3.5M | 151.0K | — |
| Operating Expenses | |||||
| R&D Expense | 75.9M | 129.6M | 173.6M | 135.3M | 87.3M |
| SG&A Expense | 40.6M | 46.8M | 40.8M | 34.8M | 27.5M |
| General & Admin Expense | 40.6M | 46.8M | 40.8M | 34.8M | 27.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (798.0K) | (4.6M) | — | — | — |
| Total Operating Expenses | 115.7M | 171.9M | 214.4M | 170.1M | 114.8M |
| Cost and Expenses | 116.5M | 173.4M | 214.4M | 170.1M | 114.8M |
| Operating Income (EBIT) | (101.5M) | 70.6M | (210.8M) | (169.9M) | (114.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 1.0K |
| Interest Expense | — | — | — | — | 1.0K |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 15.4M | 21.3M | 23.8M | 16.9M | 10.1M |
| Non-Operating Income (excl Interest) | (15.4M) | (21.3M) | (23.8M) | (16.9M) | (10.1M) |
| EBT (Pre-Tax Income) | (86.1M) | 91.9M | (187.1M) | (153.0M) | (104.7M) |
| Income Tax Expense | (2.9M) | 4.9M | 300.0K | — | — |
| Bottom Line | |||||
| Net Income | (83.2M) | 87.0M | (187.4M) | (153.0M) | (104.7M) |
| Earnings from Cont. Ops | (83.2M) | 87.0M | (187.4M) | (153.0M) | (104.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (83.2M) | 87.0M | (187.4M) | (153.0M) | (104.7M) |
| Per Share | |||||
| Basic EPS | ($3.70) | $2.34 | ($5.00) | ($5.20) | ($4.15) |
| Diluted EPS | ($3.22) | $2.30 | ($5.00) | ($5.20) | ($4.15) |
| Revenue Per Share | $0.76 | $6.56 | $0.09 | $0.01 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 19.8M | 37.2M | 37.4M | 29.4M | 25.2M |
| Diluted Shares Outstanding | 19.8M | 37.9M | 37.4M | 29.4M | 25.2M |
| Profitability Metrics | |||||
| EBITDA | (84.5M) | 93.4M | (185.8M) | (152.2M) | (104.0M) |
| D&A | 1.6M | 1.5M | 1.2M | 815.0K | 674.0K |
| EBIT | (86.1M) | 91.9M | (187.1M) | (153.0M) | (104.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026